At a glance
- What the study gets you
- Health checks and monitoring — no treatment given
- Type of study
- Observational (no treatment given)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- Prostate cancer risk gene panel (genetic)
- How long the study runs
- Study runs about 190 months (dates as stated)
- About the drug or intervention
- Prostate cancer risk gene panel — genetic: A list of genes created by study experts, thought to increase the risk of prostate cancer from from review previous research, this list is regularly reviewed for accuracy
- Patient visit burden
- Not specified by the sponsor
In plain English
This study, run by the Institute of Cancer Research in the United Kingdom, is looking at precision medicine in prostate cancer care. Precision medicine means using information about a person's genes to help guide their care. The study also covers genetic predisposition, meaning a higher chance of getting prostate cancer because it runs in the family.
Who can take part
- Men with prostate cancer diagnosed under the age of 60
- Men with metastatic castration resistant prostate cancer (cancer that has spread and no longer responds to standard hormone treatment) at any age
- Men under 70 with aggressive prostate cancer (Gleason score 4+4 or higher)
- Men with prostate cancer and a family history, meaning 3 or more cases in first-degree or second-degree relatives (such as a father, brother, uncle or grandfather) at any age
- A group of people aged over 30 with a family history of prostate cancer was also included, but this group has finished recruiting
Who may not be able to
- People with a WHO performance status of 4 (this is a scale doctors use; status 4 means the person is fully dependent on others and cannot look after themselves)
What taking part involves
- • Not stated — ask the trial team
Time commitment: Not stated — ask the trial team about what taking part involves, how many visits are needed and how long it lasts.
Plain-English summary (AI-generated) from registry data. Not eligibility advice — only the trial team can confirm whether you can take part. Use the eligibility checker to see how your health profile matches this trial.
- Type of study
- Observing health over time
- Ages
- 30 Years to 70 Years
- Who
- Male
- Number of participants
- 3,000
- Started
- 2019-02-14
- Last checked
- 2025-12
Plain English Summary
What is this study?
- • Testing a new treatment for prostate cancer
- • Clinical study - 3,000 participants
- • This study aims to evaluate the use of a prostate cancer specific predisposition genetic panel test in men with / at high risk of prostate cancer
Who can take part?
- • Ages 30 Years to 70 Years
- • Diagnosed with prostate cancer
- • Male only
Where?
- • Sutton - Royal Marsden Hosital,
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
This study aims to evaluate the use of a prostate cancer specific predisposition genetic panel test in men with / at high risk of prostate cancer. The genetic test will analyse men's DNA samples for the presence of mutations in rare genes as well as common genetic variation to provide men with information about their risk of prostate cancer. This study will evaluate the clinical impact of the test on risk assessment and clinical management in terms of screening and treatment.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 30 Years - 70 Years
- Who can join: Male only
What the study is looking for
- ✓Affected cohort:
- ✓Affected with PrCa \< 60 years or
- ✓Affected with that has spread castration resistant PrCa (mCRPC) at any age or Aggressive PrCa Gleason 4+4 or higher \<70...
- ✓Affected with family history defined as three or more cases any age (FDR or SDR)
- ✓Unaffected cohort: (This cohort is no longer recruiting, it has completed recruitment)
Who cannot take part
- ✗• WHO performance status 4
See the full criteria
Where Is This Study? (1 UK site)
Royal Marsden Hosital,
Sutton SM2 5PT, United Kingdom